Traws Pharma, Inc. 8-K

What Happened

• On January 26, 2026, Traws Pharma, Inc. announced via press release (filed on Form 8‑K) that it has completed its ongoing study of ratutrelvir, a ritonavir‑free potential treatment, in PAXLOVID®‑eligible and PAXLOVID®‑ineligible patients with mild‑to‑moderate COVID‑19. The company also announced plans to pursue an additional indication for tivoxavir marboxil as a prophylactic treatment for seasonal influenza. The press release is included as Exhibit 99.1 to the Form 8‑K.

Key Details

• Date of disclosure: January 26, 2026 (Press Release filed on Form 8‑K).
• Drug programs: ratutrelvir (ritonavir‑free antiviral) and tivoxavir marboxil (planned influenza prophylaxis indication).
• Study population: PAXLOVID®‑eligible and PAXLOVID®‑ineligible patients with mild‑to‑moderate COVID‑19.
• Filing: Press Release incorporated by reference as Exhibit 99.1 to the Current Report on Form 8‑K.

Why It Matters

• The filing reports concrete clinical‑development progress (completion of a study) and an expansion of Traws Pharma’s development plans (seeking an influenza prophylaxis indication). These are material program updates that investors typically watch because they affect the company’s clinical and regulatory activity timelines and overall pipeline development. The press release on Form 8‑K makes the information public and part of the company’s official disclosures.